These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors. Song S; Shi R; Li B; Liu Y Pancreas; 2009 Oct; 38(7):811-4. PubMed ID: 19657309 [TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and treatment of vasoactive intestinal peptide-secreting-tumors: one case report and 15 years review in China]. Li JT; Peng SY; Liu YB; Fang HQ; Wu YL; Wang XB; Tang Z; Qian HR; Ji C Zhonghua Wai Ke Za Zhi; 2004 May; 42(9):524-7. PubMed ID: 15196363 [TBL] [Abstract][Full Text] [Related]
6. [Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide]. Scheffold N; Arnold R; Cyran J Dtsch Med Wochenschr; 1995 Oct; 120(43):1463-7. PubMed ID: 7588006 [TBL] [Abstract][Full Text] [Related]
7. VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome. Nakayama S; Yokote T; Kobayashi K; Hirata Y; Hiraiwa T; Komoto I; Miyakoshi K; Yamakawa Y; Takubo T; Tsuji M; Imamura M; Hanafusa T Endocrine; 2009 Apr; 35(2):143-6. PubMed ID: 19184565 [TBL] [Abstract][Full Text] [Related]
8. Pancreatic vasoactive intestinal polypeptide-oma as a cause of secretory diarrhoea. Masel SL; Brennan BA; Turner JH; Cullingford GL; Cullen DJ J Gastroenterol Hepatol; 2000 Apr; 15(4):457-60. PubMed ID: 10824894 [TBL] [Abstract][Full Text] [Related]
9. VIPomas: an update in diagnosis and management in a series of 11 patients. Nikou GC; Toubanakis C; Nikolaou P; Giannatou E; Safioleas M; Mallas E; Polyzos A Hepatogastroenterology; 2005; 52(64):1259-65. PubMed ID: 16001675 [TBL] [Abstract][Full Text] [Related]
10. Intractable and dramatic diarrhea in liver transplantation recipient with vasoactive intestinal peptide-producing tumor after split liver transplantation: a case report. Haiqing W; Jiayin Y; Jian Y; Lunan Y Transplant Proc; 2015; 47(1):171-3. PubMed ID: 25596962 [TBL] [Abstract][Full Text] [Related]
11. Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma. Shaib W; Mitchell K; Saif MW Yale J Biol Med; 2010 Mar; 83(1):27-33. PubMed ID: 20351979 [TBL] [Abstract][Full Text] [Related]
18. Safety of Irreversible Electroporation Ablation of the Pancreas. Lee EW; Shahrouki P; Peterson S; Tafti BA; Ding PX; Kee ST Pancreas; 2021 Oct; 50(9):1281-1286. PubMed ID: 34860812 [TBL] [Abstract][Full Text] [Related]
19. An Unusual Cause of Watery Diarrhea. Nassani N; Melitas C; Villa E Gastroenterology; 2021 Feb; 160(3):671-674. PubMed ID: 33039475 [No Abstract] [Full Text] [Related]
20. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. Scheffer HJ; Vroomen LG; de Jong MC; Melenhorst MC; Zonderhuis BM; Daams F; Vogel JA; Besselink MG; van Kuijk C; Witvliet J; de van der Schueren MA; de Gruijl TD; Stam AG; van den Tol PM; van Delft F; Kazemier G; Meijerink MR Radiology; 2017 Feb; 282(2):585-597. PubMed ID: 27604035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]